Odonate Therapeutics Inc (NASDAQ:ODT) CEO Kevin C. Tang bought 90,000 shares of the firm’s stock in a transaction dated Thursday, September 20th. The stock was bought at an average cost of $19.55 per share, with a total value of $1,759,500.00. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website.
NASDAQ ODT traded up $0.16 on Friday, hitting $16.05. 41,531 shares of the stock traded hands, compared to its average volume of 53,221. Odonate Therapeutics Inc has a twelve month low of $15.15 and a twelve month high of $32.00. The stock has a market capitalization of $521.97 million and a P/E ratio of -6.95.
Odonate Therapeutics (NASDAQ:ODT) last announced its quarterly earnings data on Monday, July 30th. The company reported ($0.79) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.82) by $0.03. As a group, research analysts anticipate that Odonate Therapeutics Inc will post -3.42 EPS for the current fiscal year.
Institutional investors have recently made changes to their positions in the company. The Manufacturers Life Insurance Company acquired a new stake in shares of Odonate Therapeutics during the 1st quarter worth approximately $128,000. California State Teachers Retirement System acquired a new stake in shares of Odonate Therapeutics during the 1st quarter worth approximately $218,000. Schwab Charles Investment Management Inc. acquired a new stake in shares of Odonate Therapeutics during the 1st quarter worth approximately $605,000. Alps Advisors Inc. acquired a new stake in shares of Odonate Therapeutics during the 2nd quarter worth approximately $862,000. Finally, Northern Trust Corp acquired a new stake in shares of Odonate Therapeutics during the 1st quarter worth approximately $1,489,000. Institutional investors and hedge funds own 86.90% of the company’s stock.
Separately, Zacks Investment Research upgraded Odonate Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 25th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Odonate Therapeutics presently has an average rating of “Hold” and a consensus price target of $31.00.
About Odonate Therapeutics
Odonate Therapeutics, Inc, a pharmaceutical company, develops therapeutics for the treatment of cancer. It focuses on the development of tesetaxel, an orally administered chemotherapy agent for patients with advanced or metastatic breast cancer (MBC). Odonate Therapeutics, Inc also conducting a Phase III study in MBC, which is known as CONTESSA.
Read More: Why does a company issue an IPO?
Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.